8-K: BioLife Solutions Reports Strong Q3 Growth, Raises Cell Processing Revenue Guidance

BioLife Solutions announced a 43% year-over-year increase in Cell Processing revenue for Q3 2024 and raised its full-year guidance for this segment.

Summary

• BioLife Solutions reported a 30% increase in total revenue for the third quarter of 2024, reaching $30.6 million, compared to $23.6 million in the same period of 2023.
• Cell Processing revenue saw a significant 43% year-over-year increase, totaling $19.0 million.
• The company's GAAP gross margin was 51%, while the non-GAAP adjusted gross margin was 54%.
• BioLife Solutions reported a GAAP net loss from continuing operations of $1.7 million, but a non-GAAP adjusted EBITDA of $6.1 million, representing 20% of revenue.
• The company has increased its Cell Processing revenue guidance for 2024 by $2 million, now projecting $72.0 to $73.0 million.
• Total revenue guidance for 2024 is set at $98.0 to $100.0 million, reflecting the impact of the SciSafe divestiture.
• The company completed the sale of its SciSafe biostorage business for $73 million in cash on November 12, 2024.
• BioLife Solutions processed 16 new U.S. FDA Master File cross references for its biopreservation media, bringing the cumulative total to 744.
• Their biopreservation media is now embedded in 17 unique commercial CGTs, with an expectation of 6 additional product approvals in the next 12 months.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth in the Cell Processing segment, increased guidance, and the strategic divestiture of SciSafe. The company's focus on high-growth areas and improved profitability metrics contribute to this positive outlook.

Positives

• The company experienced its fourth consecutive quarter of sequential Cell Processing revenue growth.
• Adjusted gross and adjusted EBITDA margins have expanded.
• The sale of SciSafe allows the company to focus on its high-growth cell processing products.
• The company has a fortified balance sheet and a streamlined operational environment.
• The company is now a pure play enabler of CGTs globally.
• The company expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.

Negatives

• The company reported a GAAP net loss from continuing operations of $1.7 million for Q3 2024.
• Total revenue guidance for 2024 was revised down slightly to $98.0 $100.0 million due to the SciSafe divestiture.
• Biostorage Services platform revenue guidance was revised down to $26.0 $27.0 million due to the sale of SciSafe.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The non-GAAP financial measures used by the company may not be comparable to those used by competitors.
• The company's future performance is dependent on the continued growth of the cell and gene therapy market.

Future Outlook

BioLife Solutions expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024 and anticipates 6 additional product approvals, geographic expansions, or new indications in the next 12 months.

Management Comments

• Roderick de Greef, BioLife Chairman and CEO, stated that they are pleased to report their fourth consecutive quarter of sequential Cell Processing revenue growth and expansion of adjusted gross and adjusted EBTIDA margins.
• de Greef also mentioned that the sale of SciSafe is a major step in focusing energy and capital allocation toward their proprietary, high growth and high margin cell processing products.
• Management expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.

Industry Context

This announcement highlights BioLife Solutions' strategic shift towards focusing on its core cell processing business, aligning with the growing demand for cell and gene therapy solutions. The divestiture of SciSafe indicates a move to streamline operations and capitalize on high-growth areas within the CGT market.

Comparison to Industry Standards

• While specific competitor data isn't provided in this document, BioLife's 43% year-over-year growth in Cell Processing revenue is a strong indicator of its performance in the rapidly expanding CGT market.
• The adjusted EBITDA margin of 20% suggests efficient operations and profitability, which is a key metric for companies in this sector.
• The company's focus on biopreservation media and its integration into 17 commercial CGTs demonstrates its competitive position in providing essential tools for cell and gene therapy development.
• Companies like Cryoport and Thermo Fisher Scientific also operate in the cell and gene therapy supply chain, but BioLife's specific focus on biopreservation and cell processing tools differentiates it.

Stakeholder Impact

• Shareholders will likely view the strong Cell Processing revenue growth and increased guidance positively.
• Employees may benefit from the company's focus on high-growth areas and improved financial performance.
• Customers will continue to have access to BioLife's cell processing tools and services.
• Suppliers may see increased demand for their products as BioLife's business grows.
• Creditors may view the company's improved financial position favorably.

Next Steps

• Management will discuss the financial results and provide a business update during a conference call and webcast.
• The company will continue to focus on its cell processing business and drive revenue growth and profitability.
• The company expects 6 additional product approvals, geographic expansions, or new indications in the next 12 months.

Key Dates

Keywords

Cell Processing, Biopreservation, Cell and Gene Therapy, CGT, EBITDA, Revenue, Gross Margin, SciSafe, FDA Master File, Financial Results